Anti-Mouse CD106 (VCAM-1) (Clone M/K-2.7) – Purified in vivo PLATINUM™ Functional Grade

Stromal cells derived from mouse bone marrow

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM^TM antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

The M/K-2.7 activity is specifically directed against mouse CD106 also known as VCAM-1 and INCAM-110.

CD106 is a single-chain type I glycoprotein with a molecular weight of 110 kDa. It is upregulated in response to inflammatory stimuli and cytokines, and it plays an important role in leukocyte adhesion, transmigration, and T-cell proliferation by binding to integrins CD49d/CD29 (VLA-4) and α4β7¹. It has implications in several pathologies, including heart diseases, inflammation, and cancer metastasis². The regulation and function of CD106 in immune responses highlight its potential as a therapeutic target in treating these conditions.

The M/K-2.7 clone was developed using stromal cells derived from mouse bone marrow as the immunogen. It has been widely used in various research contexts, particularly in studies involving in vivo VCAM-1 neutralization, immunofluorescence techniques, and more. This clone demonstrates its versatility across a range of experimental setups and is a valuable tool for investigating vascular cell adhesion mechanisms and the inflammatory process. It is particularly useful for research focused on inflammatory processes, immune cell migration, and the study of vascular biology^3-6.

CD106 is predominantly expressed on activated vascular endothelial cells, as well as on various other cells including follicular and interfollicular dendritic cells, some macrophages, and bone marrow stromal cells. Its expression can also be found in non-vascular cells within joints, kidneys, muscles, the heart, the placenta, and the brain.

VLA-4 (α4/β1 integrin) and LPAM-1 (α4/β7 integrin)

1. Tolstrup A, Hokland P, Nielsen B, Justesen J, Hokland M. J Interferon Res. 1993;13(6):433-441.
2. Salajegheh A, Salajegheh A. Springer International Publishing; 2016:375-379.
3. Hession C, Moy P, Tizard R, et al. Biochem Biophys Res Commun. 1992;183(1):163-169.
4. Osborn L, Hession C, Tizard R, et al. Cell. 1989;59(6):1203-1211.
5. Miyake K, Medina K, Ishihara K, Kimoto M, Auerbach R, Kincade PW. The Journal of cell biology. 1991;114(3):557-565.
6. Kumar AG, Dai XY, Kozak CA, Mims MP, Gotto AM, Ballantyne CM. The Journal of Immunology. 1994;153(9):4088-4098.
7. Yousef H, Czupalla CJ, Lee D, et al. Nat Med. 2019;25(6):988-1000.
8. de Juan A, Ince LM, Pick R, et al. Circulation. 2019;140(13):1100-1114.
9. He W, Holtkamp S, Hergenhan SM, et al. Immunity. 2018;49(6):1175-1190.e7.
10. Kapitsinou PP, Sano H, Michael M, et al. J Clin Invest. 2014;124(6):2396-2409.
11. Chow A, Huggins M, Ahmed J, et al. Nat Med. 2013;19(4):429-436.
12. Brinkman CC, Rouhani SJ, Srinivasan N, Engelhard VH. J Immunol. 2013;191(5):2412-2425.
13. Thomas SY, Scanlon ST, Griewank KG, et al. J Exp Med. 2011;208(6):1179-1188.